Docoh
Loading...

FNCH Finch Therapeutics

Press releases

From Benzinga Pro
Finch Therapeutics to Participate in Upcoming Investor Conferences
11 Nov 21
News, Press Releases
SOMERVILLE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First
Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
10 Nov 21
Earnings, Press Releases
New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained
Finch Therapeutics Announces Transition of Chief Medical Officer
10 Nov 21
Press Releases
Zain Kassam, MD, MPH to step down as Chief Medical Officer (CMO) and will serve as a special advisor to the companyDebra Silberg, MD, PhD to transition from clinical advisor to interim CMO SOMERVILLE, Mass., Nov. 10,
Finch Therapeutics Announces Positive Topline Results from PRISM-EXT Phase 2 Trial of CP101 for Prevention of Recurrent C. difficile Infection
9 Nov 21
Press Releases, General
New data from 132-participant PRISM-EXT Phase 2 open-label trial show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks and a safety profile consistent with previously
Finch Therapeutics Presents Positive Data from PRISM3 Clinical Trial of CP101 for Recurrent C. difficile at American College of Gastroenterology Annual Scientific Meeting
25 Oct 21
Analyst Ratings, Press Releases
New data from PRISM3 Phase 2 trial show CP101 demonstrated statistically significant efficacy for prevention of recurrent C. difficile infection and a favorable safety profile through 24 weeksAdditional PRISM3 microbiome
Finch Therapeutics to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
12 Oct 21
News, Health Care, Press Releases
SOMERVILLE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
5 Oct 21
News, Management, Press Releases
SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First